Atypical neurotransmitters and the neurobiology of depression

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 8, 2015, Pages 1001-1011

  Joca, Samia Regiane ^a,b   Moreira, Fabricio Araujo ^c   Wegener, Gregers ^d,e  

^a Department of Clinical Analysis   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d AARHUS UNIVERSITY   (Denmark)

^e NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Antidepressant; Depression; Endocannabinoids; Nitric oxide; Stress

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANANDAMIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CITRULLINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOCANNABINOID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID AMIDASE; FLUOXETINE; GLUTAMIC ACID; GUANYLATE CYCLASE; IMIPRAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; N (G) METHYL DEXTRO ARGININE; N (G) NITROARGININE METHYL ESTER; N (G), N (G) DIMETHYLARGININE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURONAL NITRIC OXIDE SYNTHASE; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; PAROXETINE; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ARTICLE; BRAIN; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR DEPRESSION; MEDIAN RAPHE NUCLEUS; NEUROBIOLOGY; NEUROTRANSMISSION; NEUTROPHIL; NITRERGIC NERVE CELL; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; ANIMAL; DEPRESSIVE DISORDER; DRUG EFFECTS; METABOLISM;

ANIMALS; BRAIN; DEPRESSIVE DISORDER; HUMANS; NEUROTRANSMITTER AGENTS;

EID: 84945411429     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150909114804     Document Type: Article

References (161)

1. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011; 9: 90.
2. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year. 2000; Br J Psychiatry 2004; 184: 386-92.
3. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009; 15(14): 1563-86.
4. Himmerich H, Wranik DW. Choice of treatment with antidepressants: influencing factors. Curr Pharm Des 2012; 18(36): 5958-75.
5. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110(2): 135-370.
6. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000; 61(Suppl 6): 4-6.
7. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet 2009; 373(9665): 746-58.
8. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004; 7(2): 193-218.
9. Andrews PW, Kornstein SG, Halberstadt LJ, Gardner CO, Neale MC. Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2011; 2: 159.
10. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007; 113(1): 134-53.
11. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15(7): 220-6.
12. Duric V, Duman RS. Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell Mol Life Sci 2013; 70(1): 39-53.
13. Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci 2008; 10(4): 385-400.
14. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biol Psychiatry 2006; 59(12): 1116-27.
15. Tanti A, Belzung C. Hippocampal neurogenesis: a biomarker for depression or antidepressant effects? Methodological considerations and perspectives for future research. Cell Tissue Res 2013; 354(1): 203-19.
16. Castren E, Hen R. Neuronal plasticity and antidepressant actions. Trends Neurosci 2013; 36(5): 259-67.
17. Castren E. Is mood chemistry? Nat Rev Neurosci 2005; 6(3): 241- 6.
18. Artigas F. Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol 2015; 25(5): 657-70.
19. Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression - A central role for the serotonin transporter? Pharmacol Ther 2015; 147: 1-11.
20. Musazzi L, Treccani G, Mallei A, Popoli M. The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol Psychiatry 2013; 73(12): 1180-8.
21. Niciu MJ, Ionescu DF, Richards EM, Zarate CA Jr. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm 2014; 121(8): 907-24.
22. Baranano DE, Ferris CD, Snyder SH. Atypical neural messengers. Trends Neurosci 2001; 24(2): 99-106.
23. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988; 336(6197): 385-8.
24. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988; 12(4): 365- 72.
25. Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 1989; 86(22): 9030-3.
26. Garthwaite J, Garthwaite G, Palmer RM, Moncada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 1989; 172(4-5): 413-6.
27. Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 2005; 76(2): 126-52.
28. Abu-Soud HM, Stuehr DJ. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc Natl Acad Sci USA 1993; 90(22): 10769-72.
29. Wegener G, Mathe A. Nitric Oxide Signaling in Depression and Antidepressant Action, in Neurobiology of Depression. Lopez- Munoz F, Alamo C, Eds; 2012, CRC Press: Boca Raton; pp. 341- 70.
30. Amitai Y. Physiologic role for "inducible" nitric oxide synthase: a new form of astrocytic-neuronal interface. Glia 2010; 58(15): 1775-81.
31. Forstermann U, Boissel J, Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12(10): 773-90.
32. Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 2008; 27(11): 2783-802.
33. Borda T, Genaro A, Sterin-Borda L, Cremaschi G. Involvement of endogenous nitric oxide signalling system in brain muscarinic acetylcholine receptor activation. J Neural Transm 1998; 105(2-3): 193-204.
34. Florenzano F, Viscomi MT, Amadio S, D'Ambrosi N, Volonte C, Molinari M. Do ATP and NO interact in the CNS? Prog Neurobiol 2008; 84(1): 40-56.
35. Feil R, Kleppisch T. NO/cGMP-dependent modulation of synaptic transmission. Handb Exp Pharmacol 2008; 184: 529-60.
36. Garthwaite J. New insight into the functioning of nitric oxidereceptive guanylyl cyclase: physiological and pharmacological implications. Mol Cell Biochem 2010; 334(1-2): 221-32.
37. Kleppisch T, Feil R. cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour. Handb Exp Pharmacol 2009; 191: 549-79.
38. Lucas KA, Pitari GM, Kazerounian S. Guanylyl cyclases and signaling by cyclic GMPharmacol Rev 2000; 52(3): 375-414.
39. Ding JD, Burette A, Nedvetsky PI, Schmidt HH, Weinberg RJ. Distribution of soluble guanylyl cyclase in the rat brain. J Comp Neurol 2004; 472(4): 437-48.
40. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 1992; 46(4): 755-84.
41. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 2001; 3(2): 193-7.
42. Steinert JR, Chernova T, Forsythe ID. Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist 2010; 16(4): 435-52.
43. Orlando GF, Wolf G, Engelmann M. Role of neuronal nitric oxide synthase in the regulation of the neuroendocrine stress response in rodents: insights from mutant mice. Amino Acids 2008; 35(1): 17- 27.
44. Bilbo SD, Hotchkiss AK, Chiavegatto S, Nelson RJ. Blunted stress responses in delayed type hypersensitivity in mice lacking the neuronal isoform of nitric oxide synthase. J Neuroimmunol 2003; 140(1-2): 41-8.
45. Juch M, Smalla KH, Kahne T. Congenital lack of nNOS impairs long-term social recognition memory and alters the olfactory bulb proteome. Neurobiol Learn Memory 2009; 92(4): 469-84.
46. Nelson RJ. Effects of nitric oxide on the HPA axis and aggression. 2005; 268: 147-60.
47. Nelson RJ, Demas GE, Huang PL. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 1995; 378(6555): 383-6.
48. Nelson RJ, Trainor BC, Chiavegatto S, Demas GE. Pleiotropic contributions of nitric oxide to aggressive behavior. Neurosci Biobehav Rev 2006; 30(3): 346-55.
49. Tanda K, Nishi A, Matsuo N, et al. Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1- mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice. Mol Brain 2009; 2(1): 19.
50. Weitzdoerfer R, Hoeger H, Engidawork E, et al. Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance. Nitric Oxide 2004; 10(3): 130-40.
51. Zhang J, Huang XY, Ye ML, et al. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J Neurosci 2010; 30(7): 2433-41.
52. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the 'kindling' hypothesis. Am J Psychiatry 2000; 157(8): 1243-51.
53. Harvey BH, et al. Involvement of the NMDA receptor, NO-cyclic GMP and nuclear factor K-beta in an animal model of repeated trauma. Hum Psychopharmacol Clin Exp 2005; 20(5): 367-73.
54. Harvey BH, Oosthuizen F, Brand L, Wegener G, Stein DJ. Stressrestress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology 2004; 175(4): 494-502.
55. Madrigal JL, Moro MA, Lizasoain I, et al. Inducible nitric oxide synthase expression in brain cortex after acute restraint stress is regulated by nuclear factor kappaB-mediated mechanisms. J Neurochem 2001; 76(2): 532-8.
56. Madrigal JLM, Moro MA, Lizasoain I, Lorenzo P, Leza JC. Stressinduced increase in extracellular sucrose space in rats is mediated by nitric oxide. Brain Res 2002; 938(1-2): 87-91.
57. Wegener G, Harvey BH, Bonefeld B, et al. Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. Int J Neuropsychopharmacol 2010; 13(4): 461-73.
58. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005; 4(2): 141-94.
59. Arevalo R, Sanchez F, Alonso JR, Carretero J, Vazquez R, Aijon J. NADPH-diaphorase activity in the hypothalamic magnocellular neurosecretory nuclei of the rat. Brain Res Bull 1992; 28(4): 599- 603.
60. Bhat G, Mahesh VB, Aguan K, Brann DW. Evidence that brain nitric oxide synthase is the major nitric oxide synthase isoform in the hypothalamus of the adult female rat and that nitric oxide potently regulates hypothalamic cGMP levels. Neuroendocrinology 1996; 64(2): 93-102.
61. Ceccatelli S, Grandison L, Scott RE, Pfaff DW, Kow LM. Estradiol regulation of nitric oxide synthase mRNAs in rat hypothalamus. Neuroendocrinology 1996; 64(5): 357-63.
62. Nylen A, Skagerberg G, Alm P, Larsson B, Holmqvist B, Andersson KE. Nitric oxide synthase in the hypothalamic paraventricular nucleus of the female rat; organization of spinal projections and coexistence with oxytocin or vasopressin. Brain Res 2001; 908(1): 10-24.
63. Tsuchiya T, Kishimoto J, Nakayama Y. Marked increases in neuronal nitric oxide synthase (nNOS) mRNA and NADPHdiaphorase histostaining in adrenal cortex after immobilization stress in rats. Psychoneuroendocrinology 1996; 21(3): 287-93.
64. Costa A, Trainer P, Besser M, Grossman A. Nitric oxide modulates the release of corticotropin-releasing hormone from the rat hypothalamus in vitro. Brain Res 1993; 605(2): 187-92.
65. Rivier C, Shen GH. In the rat, endogenous nitric oxide modulates the response of the hypothalamic-pituitary-adrenal axis to interleukin-1β, vasopressin, and oxytocin. J Neurosci 1994; 14(4): 1985-93.
66. Okada S, Murakami Y, Yokotani K. Centrally applied nitric oxide donor elevates plasma corticosterone by activation of the hypothalamic noradrenergic neurons in rats. Brain Res 2002; 939(1-2): 26-33.
67. Seo DO, Rivier C. Microinfusion of a nitric oxide donor in discrete brain regions activates the hypothalamic-pituitary-adrenal axis. J Neuroendocrinol 2001; 13(11): 925-33.
68. Givalois L, Li S, Pelletier G. Central nitric oxide regulation of the hypothalamic-pituitary-adrenocortical axis in adult male rats. Mol Brain Res 2002; 102(1-2): 1-8.
69. Tsuchiya T, Kishimoto J, Koyama J, Ozawa T. Modulatory effect of L-NAME, a specific nitric oxide synthase (NOS) inhibitor, on stress-induced changes in plasma adrenocorticotropic hormone (ACTH) and corticosterone levels in rats: physiological significance of stress-induced NOS activation in hypothalamicpituitary- adrenal axis. Brain Res 1997; 776(1-2): 68-74.
70. Bugajski J, Gadek-Michalska A, Bugajski AJ. Nitric oxide and prostaglandin systems in the stimulation of hypothalamic-pituitaryadrenal axis by neurotransmitters and neurohormones. J Physiol Pharmacol 2004; 55(4): 679-703.
71. Mancuso C, Navarra P, Preziosi P. Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem 2010; 113(3): 563-75.
72. Rivier C. Role of gaseous neurotransmitters in the hypothalamicpituitary- adrenal axis. Ann NY Acad Sci 2001; 933: 254-64.
73. Rivier C. Role of nitric oxide in regulating the rat hypothalamicpituitary- adrenal axis response to endotoxemia. Ann NY Acad Sci 2003; 992: 72-85.
74. Sanchez F, Moreno MN, Vacas P, Carretero J, Vazquez R. Swim stress enhances the NADPH-diaphorase histochemical staining in the paraventricular nucleus of the hypothalamus. Brain Res 1999; 828(1-2): 159-162.
75. Zhou QG, Zhu LJ, Chen C, et al. Hippocampal neuronal nitric oxide synthase mediates the stress-related depressive behaviors of glucocorticoids by downregulating glucocorticoid receptor. J Neurosci 2011; 31(21): 7579-90.
76. Montezuma K, Biojone C, Lisboa SF, Cunha FQ, Guimaraes FS, Joca SR. Inhibition of iNOS induces antidepressant-like effects in mice: pharmacological and genetic evidence. Neuropharmacology 2012; 62(1): 485-91.
77. Abu-Ghanem Y, Cohen H, Buskila Y, Grauer E, Amitai Y. Enhanced stress reactivity in nitric oxide synthase type 2 mutant mice: findings in support of astrocytic nitrosative modulation of behavior. Neuroscience 2008; 156(2): 257-65.
78. Buskila Y, Abu-Ghanem Y, Levi Y, Moran A, Grauer E, Amitai Y. Enhanced astrocytic nitric oxide production and neuronal modifications in the neocortex of a NOS2 mutant mouse. PLoS One 2007; 2(9): e843.
79. Gadek-Michalska A, Tadeusz J, Rachwalska P, Spyrka J, Bugajski J. Effect of repeated restraint on homotypic stress-induced nitric oxide synthases expression in brain structures regulating HPA axis. Pharmacol Rep 2012; 64(6): 1381-90.
80. Madrigal JL, Moro MA, Lizasoain I, et al. Inducible nitric oxide synthase expression in brain cortex after acute restraint stress is regulated by nuclear factor kappaB-mediated mechanisms. J Neurochem 2001; 76(2): 532-8.
81. Zlatkovic J, Filipovic D. Chronic social isolation induces NFkappaB activation and upregulation of iNOS protein expression in rat prefrontal cortex. Neurochem Int 2013; 63(3): 172-9.
82. Gadek-Michalska A, Spyrka J, Bugajski J. Psychosocial stress affects the involvement of prostaglandins and nitric oxide in the lipopolysaccharide-induced hypothalamic-pituitary-adrenal response. J Physiol Pharmacol 2005; 56(2): 287-98.
83. Kaehler ST, Singewald N, Sinner C, Philippu A. Nitric oxide modulates the release of serotonin in the rat hypothalamus. Brain Res 1999; 835(2): 346-9.
84. Lorrain DS, Hull EM. Nitric oxide increases dopamine and serotonin release in the medial preoptic area. Neuroreport 1993; 5(1): 87-9.
85. Segovia G, Del Arco A, Mora F. Endogenous glutamate increases extracellular concentrations of dopamine, GABA, and taurine through NMDA and AMPA/kainate receptors in striatum of the freely moving rat: a microdialysis study. J Neurochem 1997; 69(4): 1476-83.
86. Segovia G, Del Arco A, Mora F. Role of glutamate receptors and glutamate transporters in the regulation of the glutamate-glutamine cycle in the awake rat. Neurochem Res 1999; 24(6): 779-83.
87. Segovia G, Porras A, Mora F. Effects of a nitric oxide donor on glutamate and GABA release in striatum and hippocampus of the conscious rat. Neuroreport 1994; 5(15): 1937-40.
88. Strasser A, McCarron RM, Ishii H, Stanimirovic D, Spatz M. Larginine induces dopamine release from the striatum in vivo. Neuroreport 1994; 5(17): 2298-300.
89. Wegener G, Volke V, Rosenberg R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 2000; 130(3): 575-80.
90. Fossier P, Blanchard B, Ducrocq C, Leprince C, Tauc L, Baux G. Nitric oxide transforms serotonin into an inactive form and this affects neuromodulation. Neuroscience 1999; 93(2): 597-603.
91. Kuhn DM, Arthur R Jr. Molecular mechanism of the inactivation of tryptophan hydroxylase by nitric oxide: attack on critical sulfhydryls that spare the enzyme iron center. J Neurosci 1997; 17(19): 7245-51.
92. Kuhn DM, Arthur RE Jr. Inactivation of brain tryptophan hydroxylase by nitric oxide. J Neurochem 1996; 67(3): 1072-7.
93. Meffert MK, Calakos NC, Scheller RH, Schulman H. Nitric oxide modulates synaptic vesicle docking fusion reactions. Neuron 1996; 16(6): 1229-36.
94. Meffert MK, Premack BA, Schulman H. Nitric oxide stimulates Ca(2+)-independent synaptic vesicle release. Neuron 1994; 12(6): 1235-44.
95. Pogun S, Baumann MH, Kuhar MJ. Nitric oxide inhibits [3H]dopamine uptake. Brain Res 1994; 641(1): 83-91.
96. Pogun S, Dawson V, Kuhar MJ. Nitric oxide inhibits 3H-glutamate transport in synaptosomes. Synapse 1994; 18(1): 21-6.
97. Pogun S, Kuhar MJ. Regulation of neurotransmitter reuptake by nitric oxide. Ann NY Acad Sci 1994; 738: 305-15.
98. Lonart G, Cassels KL, Johnson KM. Nitric oxide induces calciumdependent [3H]dopamine release from striatal slices. J Neurosci Res 1993; 35(2): 192-8.
99. Lonart G, Johnson KM. Inhibitory effects of nitric oxide on the uptake of [3H]dopamine and [3H]glutamate by striatal synaptosomes. J Neurochem 1994; 63(6): 2108-17.
100. Chanrion B, Mannoury la Cour C, Bertaso F, et al. Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity. Proc Natl Acad Sci USA 2007; 104(19): 8119-24.
101. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32(4): 653-8.
102. Krass M, Wegener G, Vasar E, Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011; 218(1): 57-63.
103. Wegener G, Volke V, Harvey BH, Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 2003; 959(1): 128-34.
104. Harkin AJ, Bruce KH, Craft B, Paul IA. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999; 372(3): 207-13.
105. Liebenberg N, Joca S, Wegener G. Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders Sensitive Line rat model of depression. Acta Neuropsychiatr 2015; 27(2): 90-6.
106. Silva M, Aguiar DC, Diniz CR, Guimaraes FS, Joca SR. Neuronal NOS inhibitor and conventional antidepressant drugs attenuate stress-induced fos expression in overlapping brain regions. Cell Mol Neurobiol 2012; 32(3): 443-53.
107. Li YF, Zhang YZ, Liu YQ, et al. Inhibition of N-methyl-Daspartate receptor function appears to be one of the common actions for antidepressants. J Psychopharmacol 2006; 20(5): 629- 35.
108. Harkin A, Connor TJ, Walsh M, St John N, Kelly JP. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003; 44(5): 616-23.
109. Wegener G, Volke V. Nitric Oxide Synthase Inhibitors as Antidepressants. Pharmaceuticals 2010; 3(1): 273-99.
110. Joca SR, Guimaraes FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology 2006; 185(3): 298-305.
111. Harkin A, Connor TJ, Burns MP, Kelly JP. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 2004; 14(4): 274-81.
112. Hiroaki-Sato VA, Sales AJ, Biojone C, Joca SR. Hippocampal nNOS inhibition induces an antidepressant-like effect: involvement of 5HT1A receptors. Behav Pharmacol 2014; 25(3): 187-96.
113. Krass M, Wegener G, Vasar E, Volke V. Antidepressant-like effect of agmatine is not mediated by serotonin. Behav Brain Res 2008; 188(2): 324-8.
114. Pinnock SB, Balendra R, Chan M, Hunt LT, Turner-Stokes T, Herbert J. Interactions between nitric oxide and corticosterone in the regulation of progenitor cell proliferation in the dentate gyrus of the adult rat. Neuropsychopharmacology 2007; 32(2): 493-504.
115. Pinnock SB, Herbert J. Brain-derived neurotropic factor and neurogenesis in the adult rat dentate gyrus: interactions with corticosterone. Eur J Neurosci 2008; 27(10): 2493-500.
116. Zhou QG, Hu Y, Hua Y, et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem 2007; 103(5): 1843-54.
117. Cardenas A, Moro MA, Hurtado O, Leza JC, Lizasoain I. Dual role of nitric oxide in adult neurogenesis. Brain Res Brain Res Rev 2005; 50(1): 1-6.
118. Bernstein HG, Heinemann A, Krell D, et al. Further immunohistochemical evidence for impaired NO signaling in the hypothalamus of depressed patients. Ann NY Acad Sci 2002; 973: 91-3.
119. Bernstein HG, Stanarius A, Baumann B, et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998; 83(3): 867-75.
120. Xing G, Chavko M, Zhang LX, Yang S, Post RM. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 2002; 58(1): 21-30.
121. Karolewicz B, Szebeni K, Stockmeier CA, et al. Low nNOS protein in the locus coeruleus in major depression. J Neurochem 2004; 91(5): 1057-66.
122. Oliveira RM, Guimaraes FS, Deakin JF. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008; 41(4): 333-41.
123. Kim YK, Paik JW, Lee SW, Yoon D, Han C, Lee BH. Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 1091-6.
124. Lee BH, Lee SW, Yoon D, et al. Increased plasma nitric oxide metabolites in suicide attempters. Neuropsychobiology 2006; 53(3): 127-32.
125. Suzuki E, Yagi G, Nakaki T, Kanba S, Asai M. Elevated plasma nitrate levels in depressive states. J Affect Disord 2001; 63(1-3): 221-4.
126. Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007; 38(2): 247-52.
127. Suzuki E, Yoshida Y, Shibuya A, Miyaoka H. Nitric oxide involvement in depression during interferon-alpha therapy. Int J Neuropsychopharmacol 2003; 6(4): 415-9.
128. Srivastava N, Barthwal MK, Dalal PK, et al. A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord 2002; 72(1): 45-52.
129. Wallerath T, Gath I, Aulitzky WE, Pollock JS, Kleinert H, Forstermann U. Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets. Thromb Haemost 1997; 77(1): 163-7.
130. Chrapko W, Jurasz P, Radomski MW, et al. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006; 31(6): 1286-93.
131. Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Melledo JM. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004; 56(2): 129-34.
132. Gao SF, Qi XR, Zhao J, Balesar R, Bao AM, Swaab DF. Decreased NOS1 expression in the anterior cingulate cortex in depression. Cereb Cortex 2013; 23(12): 2956-64.
133. Boger RH, Diemert A, Schwedhelm E, Luneburg N, Maas R, Hecher K. The Role of Nitric Oxide Synthase Inhibition by Asymmetric Dimethylarginine in the Pathophysiology of Preeclampsia. Gynecol Obstet Invest 2009; 69(1): 1-13.
134. Boger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-An update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009; 60(6): 481-7.
135. Boger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119(12): 1592-600.
136. Arlt S, Schulze F, Eichenlaub M, et al. Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2008; 26(1): 58-64.
137. Das I, Khan NS, Puri BK, Hirsch SR. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci Lett 1996; 215(3): 209-11.
138. Selley ML. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affect Disord 2004; 80(2-3): 249-56.
139. Yu YW, Chen TJ, Wang YC, Liou YJ, Hong CJ, Tsai SJ. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology 2003; 47(3): 137-40.
140. Okumura T, Kishi T, Okochi T, et al. Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. Neuropsychobiology 2010; 61(2): 57-63.
141. Sullivan PF, de Geus EJ, Willemsen G, et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry 2009; 14(4): 359-75.
142. Galecki P, Maes M, Florkowski A, et al. Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. J Affect Disord 2011; 129(1-3): 175- 82.
143. Galecki P, Maes M, Florkowski A, et al. An inducible nitric oxide synthase polymorphism is associated with the risk of recurrent depressive disorder. Neurosci Lett 2010; 486(3): 184-7.
144. Mechoulam R, Hanuš LO, Pertwee R, Howlett AC. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci 2014; 15(11): 757-64.
145. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54(2): 161-202.
146. Marco EM, Garcia-Gutierrez MS, Bermudez-Silva FJ, et al. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci 2011; 5: 63.
147. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 2005; 16(5-6): 333-52.
148. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005; 15(6): 593-9.
149. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005; 115(11): 3104-16.
150. Bambico FR, Katz N, Debonnel G, Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007; 27(43): 11700-11.
151. Haring M, Grieb M, Monory K, Lutz B, Moreira FA. Cannabinoid CB(1) receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations. Neuropharmacology 2013; 65: 83-9.
152. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Correa FM, Guimaraes FS. 5-HT1A receptors are involved in the cannabidiolinduced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 2009; 156(1): 181-8.
153. Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 2010; 159(1): 122-8.
154. Campos AC, Ortega Z, Palazuelos J, et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol 2013; 16(6): 1407-19.
155. Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 2009; 31(2): 145-53.
156. Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005; 102(51): 18620-5.
157. Hill MN, Kumar SA, Filipski SB, et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 2013; 18(10): 1125-35.
158. Onaivi ES, Ishiguro H, Gong JP, et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 2008; 3(2): e1640.
159. Moreira FA, Aguiar DC, Terzian AL, Guimaraes FS, Wotjak CT. Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin? Neuroscience 2012; 204: 186-92.
160. Kasckow JW, Mulchahey JJ, Geracioti TD, Jr. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(2): 291-5.
161. Navarria A, Tamburella A, Iannotti FA, et al. The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. Pharmacol Res 2014; 87: 151-9.